[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fpGsbo_BXmwV6teTBJipIQB6gt6wrF3fs9r-1BnX3OQ8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":31,"phaseBuckets":32,"rows":39},"Federal University of Uberlandia",[4],60,false,6,0,4979,54,[13,15,18,21,23,25,27,29],{"name":14,"count":8},"Menopause",{"name":16,"count":17},"Hypertension",5,{"name":19,"count":20},"Sarcopenia",3,{"name":22,"count":20},"Hypersensitivity Dentin",{"name":24,"count":20},"Dentin Sensitivity",{"name":26,"count":20},"Dentin Hypersensitivity",{"name":28,"count":20},"Dentine Hypersensitivity",{"name":30,"count":20},"MTA",[],[33,34,35,36,37,38],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[40,68,86,112,130,157,175,201,219,244,262],{"intervention":41,"totalTrials":42,"cells":43},"Resin modified glass ionomer",1,{"EARLY_PHASE1":44,"PHASE1":46,"PHASE2":48,"PHASE3":50,"PHASE4":52,"NA":54},{"trials":45,"activeCount":9},[],{"trials":47,"activeCount":9},[],{"trials":49,"activeCount":9},[],{"trials":51,"activeCount":9},[],{"trials":53,"activeCount":9},[],{"trials":55,"activeCount":9},[56],{"nctId":57,"briefTitle":58,"status":59,"phases":60,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":65,"interventions":66},"NCT02931734","Assessment of Different Protocols for Cervical Dentin Hypersensitivity Treatment","COMPLETED",[38],"2015-01","2015-07","2014-10",140,[22,24,26,28],[41,67],"Potassium Nitrate 2%",{"intervention":67,"totalTrials":42,"cells":69},{"EARLY_PHASE1":70,"PHASE1":72,"PHASE2":74,"PHASE3":76,"PHASE4":78,"NA":80},{"trials":71,"activeCount":9},[],{"trials":73,"activeCount":9},[],{"trials":75,"activeCount":9},[],{"trials":77,"activeCount":9},[],{"trials":79,"activeCount":9},[],{"trials":81,"activeCount":9},[82],{"nctId":57,"briefTitle":58,"status":59,"phases":83,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":84,"interventions":85},[38],[22,24,26,28],[41,67],{"intervention":87,"totalTrials":42,"cells":88},"Hydrogen peroxide 35%",{"EARLY_PHASE1":89,"PHASE1":91,"PHASE2":93,"PHASE3":95,"PHASE4":97,"NA":99},{"trials":90,"activeCount":9},[],{"trials":92,"activeCount":9},[],{"trials":94,"activeCount":9},[],{"trials":96,"activeCount":9},[],{"trials":98,"activeCount":9},[],{"trials":100,"activeCount":9},[101],{"nctId":102,"briefTitle":103,"status":59,"phases":104,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":110},"NCT03194984","Effectiveness of Office Bleaching Agents in Patients of Different Age Group",[38],"2018-01-30","2017-05-15",56,[109],"Satisfaction",[87,111],"Hydrogen peroxide 38%",{"intervention":111,"totalTrials":42,"cells":113},{"EARLY_PHASE1":114,"PHASE1":116,"PHASE2":118,"PHASE3":120,"PHASE4":122,"NA":124},{"trials":115,"activeCount":9},[],{"trials":117,"activeCount":9},[],{"trials":119,"activeCount":9},[],{"trials":121,"activeCount":9},[],{"trials":123,"activeCount":9},[],{"trials":125,"activeCount":9},[126],{"nctId":102,"briefTitle":103,"status":59,"phases":127,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":128,"interventions":129},[38],[109],[87,111],{"intervention":131,"totalTrials":42,"cells":132},"UltraEZ",{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":139,"PHASE4":141,"NA":143},{"trials":134,"activeCount":9},[],{"trials":136,"activeCount":9},[],{"trials":138,"activeCount":9},[],{"trials":140,"activeCount":9},[],{"trials":142,"activeCount":9},[],{"trials":144,"activeCount":9},[145],{"nctId":146,"briefTitle":147,"status":148,"phases":149,"primaryCompletion":150,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":155},"NCT03076944","Evaluation of Desensitization Protocols in Reduction of Dentin Hypersensitivity","UNKNOWN",[38],"2017-11","2018-03","2017-03-20",32,[22,24,26,28],[131,156],"Enamelast",{"intervention":156,"totalTrials":42,"cells":158},{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":163,"PHASE3":165,"PHASE4":167,"NA":169},{"trials":160,"activeCount":9},[],{"trials":162,"activeCount":9},[],{"trials":164,"activeCount":9},[],{"trials":166,"activeCount":9},[],{"trials":168,"activeCount":9},[],{"trials":170,"activeCount":9},[171],{"nctId":146,"briefTitle":147,"status":148,"phases":172,"primaryCompletion":150,"completion":151,"start":152,"enrollment":153,"conditions":173,"interventions":174},[38],[22,24,26,28],[131,156],{"intervention":176,"totalTrials":42,"cells":177},"Oropharyngeal administration of own mother's colostrum",{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":188},{"trials":179,"activeCount":9},[],{"trials":181,"activeCount":9},[],{"trials":183,"activeCount":9},[],{"trials":185,"activeCount":9},[],{"trials":187,"activeCount":9},[],{"trials":189,"activeCount":9},[190],{"nctId":191,"briefTitle":192,"status":59,"phases":193,"primaryCompletion":194,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":199},"NCT02912585","Oropharyngeal Administration of Colostrum",[38],"2016-07","2013-07",145,[198],"Health Behavior",[176,200],"Oropharyngeal administration of donor human milk",{"intervention":200,"totalTrials":42,"cells":202},{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":209,"PHASE4":211,"NA":213},{"trials":204,"activeCount":9},[],{"trials":206,"activeCount":9},[],{"trials":208,"activeCount":9},[],{"trials":210,"activeCount":9},[],{"trials":212,"activeCount":9},[],{"trials":214,"activeCount":9},[215],{"nctId":191,"briefTitle":192,"status":59,"phases":216,"primaryCompletion":194,"completion":194,"start":195,"enrollment":196,"conditions":217,"interventions":218},[38],[198],[176,200],{"intervention":220,"totalTrials":42,"cells":221},"Potassium Oxalate 5%",{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":230,"NA":232},{"trials":223,"activeCount":9},[],{"trials":225,"activeCount":9},[],{"trials":227,"activeCount":9},[],{"trials":229,"activeCount":9},[],{"trials":231,"activeCount":9},[],{"trials":233,"activeCount":9},[234],{"nctId":235,"briefTitle":236,"status":148,"phases":237,"primaryCompletion":238,"completion":239,"start":240,"enrollment":153,"conditions":241,"interventions":242},"NCT03083496","Clinical Evaluation of Different Potassium Oxalate Concentrations in Dentin Hypersensitivity Treatment",[38],"2017-06","2018-02","2017-03-14",[24,22,28,26],[220,243],"Potassium Oxalate 10%",{"intervention":243,"totalTrials":42,"cells":245},{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":252,"PHASE4":254,"NA":256},{"trials":247,"activeCount":9},[],{"trials":249,"activeCount":9},[],{"trials":251,"activeCount":9},[],{"trials":253,"activeCount":9},[],{"trials":255,"activeCount":9},[],{"trials":257,"activeCount":9},[258],{"nctId":235,"briefTitle":236,"status":148,"phases":259,"primaryCompletion":238,"completion":239,"start":240,"enrollment":153,"conditions":260,"interventions":261},[38],[24,22,28,26],[220,243],{"intervention":263,"totalTrials":42,"cells":264},"Mite, Mite and Bacterial or Placebo",{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":273,"NA":275},{"trials":266,"activeCount":9},[],{"trials":268,"activeCount":9},[],{"trials":270,"activeCount":9},[],{"trials":272,"activeCount":9},[],{"trials":274,"activeCount":9},[],{"trials":276,"activeCount":9},[277],{"nctId":278,"briefTitle":279,"status":59,"phases":280,"primaryCompletion":281,"completion":282,"start":283,"enrollment":284,"conditions":285,"interventions":287},"NCT01506843","Sublingual Immunotherapy in Children With Allergic Rhinitis",[38],"2010-10","2011-04","2008-10",122,[286],"Allergic Rhinitis",[263]]